Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)

ALS Clinical Trial

— EpidALS  

Official title:

Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03366506
• Other study ID #: 0633-08-HMO-CTIL
• Status: Recruiting
• Start date: March 9, 2009
• Est. completion date: January 2050

Study information

• Verified date: February 2021
• Source: Hadassah Medical Organization
• Contact: Marc Gotkine, MBBS
• Phone: +972507874692
• Email: marc[@]gotkine.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (ALS) in Israel with a view to future international collaboration. Particularly addressing:-

1. Differences between ethnic subgroups

2. Differences between immigrant and native-born populations

3. Differences according to military service profile Clinical features gathered at each routine visit ,throughout the entire course of the disease, will be recorded in database format, in order to correlate with potential epidemiological factors.

Description:

Investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (ALS) in Israel with a view to future international collaboration. Particularly addressing:-

1. Differences between ethnic subgroups

2. Differences between immigrant and native-born populations

3. Differences according to military service profile Clinical features gathered at each routine visit ,throughout the entire course of the disease, will be recorded in database format, in order to correlate with potential epidemiological factors.

The clinical features will include pattern of onset, details of full clinical exam ( including ALSFRS-R score, power, reflexes, and other signs of upper or lower-motor neuron dysfunction.

Correlations between different clinical parameters themselves will be made, as well as correlation between clinical parameters and other epidemiological factors.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2000
• Est. completion date: January 2050
• Est. primary completion date: March 2049
• Gender: All
• Age group: 12 Years to 120 Years

Eligibility

Inclusion Criteria:

• Suspected, possible, probable ,definite ALS

Exclusion Criteria:

-

Related Conditions & MeSH terms

• ALS
• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease

Intervention

Other:
• Observation

Locations

Country	Name	City	State
Israel	Hadassah Medical Organisation	Jerusalem

Sponsors (1)

Lead Sponsor	Collaborator
Hadassah Medical Organization

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression rate	Progression of ALSFRS-R score over time	up to 10 years
Secondary	Appearance of clinical features of UMN or LMN dysfunction	Appearance of clinical features of UMN or LMN dysfunction over time	10 years